Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[S,S]-Reboxetine in Fibromyalgia
NCT00357825Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2006
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibromyalgia (FM) comparing Esreboxetine with Placebo (2 arms). Primary endpoint: Weekly Average Pain Score from the Daily Pain Diary at 8 weeks. Started Aug 2006; status: completed.
02
Drugs
esreboxetine
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT00357825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00357825.